Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rifapentine
Drug ID BADD_D01937
Description Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Indications and Usage For the treatment of pulmonary tuberculosis.
Marketing Status approved; investigational
ATC Code J04AB05
DrugBank ID DB01201
KEGG ID D00879
MeSH ID C018421
PubChem ID 135403821
TTD Drug ID D0G9IU
NDC Product Code 40074-0009; 0088-2102; 50090-5063; 68022-7055; 53002-1718
UNII XJM390A33U
Synonyms rifapentine | 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin | 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin SV | DL 473-IT | Rifapex | Priftin | DL 473 | DL-4-73 | MDL 473
Chemical Information
Molecular Formula C47H64N4O12
CAS Registry Number 61379-65-5
SMILES CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C) OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C6CCCC6)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Vulvovaginal pruritus23.03.12.009; 21.08.02.004--Not Available
Rectal tenesmus07.03.03.001; 15.05.03.011--Not Available
Lung neoplasm malignant16.19.02.001; 22.08.01.001--Not Available
Vasodilation procedure25.03.01.001--Not Available
Congenital eye disorder06.08.03.011; 03.01.01.002--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Porphyrin metabolism disorder14.14.01.006; 09.01.10.004; 03.08.01.006--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Hyperlipidaemia14.08.03.001--
Increased bronchial secretion22.12.01.002--Not Available
Cystitis noninfective20.03.02.001--
Breath sounds abnormal13.15.01.008--Not Available
Bronchial hyperreactivity22.03.01.016--Not Available
Anorectal discomfort07.03.03.003--Not Available
Oropharyngeal pain07.05.05.004; 22.12.03.016--
Product contamination with body fluid27.02.01.001--Not Available
Oesophageal irritation07.08.05.004--Not Available
Liver function test increased13.03.04.031--Not Available
Cross sensitivity reaction10.01.01.0360.001027%Not Available
Vulvovaginal inflammation21.14.02.014--Not Available
The 8th Page    First    Pre   8    Total 8 Pages